Eupraxia Pharmaceuticals (EPRX) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and technology

• Focus on gastroenterologic diseases, especially eosinophilic esophagitis (EoE), using Diffusphere technology for hyper-local, steady-state drug delivery over up to a year.

• Diffusphere enables zero-order kinetics, reducing side effects and improving efficacy and safety.

EoE disease landscape and diagnosis

• EoE prevalence is rising due to both increased awareness and earlier diagnosis by general gastroenterologists.

• Earlier diagnosis is driven by education efforts and improved recognition of symptoms in the community.

• Guidelines now recommend annual endoscopies for EoE patients, with about 60% compliance so far.

Clinical endpoints and measurement

• Patient symptom improvement is best measured by the Straumann Dysphagia Index (SDI) and Dysphagia Symptom Questionnaire (DSQ), both well-validated.

• Histological improvement is now more closely tracked by EoEHSS, which correlates better with symptom relief than eosinophil counts.